Education
About Us
Working with TipRanks
Follow Us
Vir Biotechnology (VIR)
NASDAQ:VIR
VIR Stock Chart & Stats
$9.10
$5.76(73.00%)
At close: 4:00 PM EST
$9.10
$5.76(73.00%)
Day’s Range― - ―
52-Week Range$4.16 - $10.94
Previous CloseN/A
Volume25.73M
Average Volume (3M)5.23M
Market Cap
$1.45B
Enterprise Value$1.41B
Total Cash (Recent Filing)$462.86M
Total Debt (Recent Filing)$186.91M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Apr 30, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding159,811,400
10 Day Avg. Volume2,974,617
30 Day Avg. Volume5,228,625
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.09
Price to Sales (P/S)12.18
P/FCF Ratio-2.11
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue20.52
Enterprise Value/Gross Profit20.53
Enterprise Value/Ebitda-3.12
Forecast
1Y Price Target
$20.86Price Target Upside129.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.18
Revenue Forecast (FY)$110.61M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy SignalsDose-dependent tumor marker and radiologic responses at planned dose levels suggest the therapy may deliver meaningful anti-tumor activity compared with current later-line options.
Safety Profile And Platform ValidationFavorable tolerability with low rates of severe immune-related events along with PRO-XTEN masking proof-of-concept supports a wider therapeutic window for masked T‑cell engagers.
Strategic Partnership And FinancingA collaboration with a major pharmaceutical partner provides substantial upfront and milestone payments while sharing global development costs, reducing financing pressure and lowering execution risk.
Bears Say
Competitive Landscape PressureEstablished comparators in prostate cancer set high efficacy and safety benchmarks, increasing the challenge for the therapy to demonstrate clear clinical superiority.
Durability Of Response UncertaintyUncertainty about the durability of responses and whether tumor marker improvements convert into sustained clinical benefit keeps long-term value unclear.
Immature Progression DataProgression-free survival data remain immature and limited long-term follow-up creates risk that early responses may not translate into durable outcomes.
Vir Biotechnology News
VIR FAQ
What was Vir Biotechnology’s price range in the past 12 months?
Vir Biotechnology lowest stock price was $4.16 and its highest was $10.94 in the past 12 months.
What is Vir Biotechnology’s market cap?
Vir Biotechnology’s market cap is $1.45B.
When is Vir Biotechnology’s upcoming earnings report date?
Vir Biotechnology’s upcoming earnings report date is Apr 30, 2026 which is in 38 days.
How were Vir Biotechnology’s earnings last quarter?
Vir Biotechnology released its earnings results on Feb 23, 2026. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.491 by $0.181.
Is Vir Biotechnology overvalued?
According to Wall Street analysts Vir Biotechnology’s price is currently Undervalued.
Does Vir Biotechnology pay dividends?
Vir Biotechnology does not currently pay dividends.
What is Vir Biotechnology’s EPS estimate?
Vir Biotechnology’s EPS estimate is -0.1.
How many shares outstanding does Vir Biotechnology have?
Vir Biotechnology has 159,811,400 shares outstanding.
What happened to Vir Biotechnology’s price movement after its last earnings report?
Vir Biotechnology reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.491. Following the earnings report the stock price went up 27.725%.
Which hedge fund is a major shareholder of Vir Biotechnology?
Currently, no hedge funds are holding shares in VIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vir Biotechnology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.86 (129.23% Upside)
$20.86 (129.23% Upside)
Blogger Sentiment
Neutral
VIR Sentiment 50%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 27.5%
Last 30 Days ▲ 27.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.45%
12-Months-Change
Fundamentals
Return on Equity
-49.31%
Trailing 12-Months
Asset Growth
-28.00%
Trailing 12-Months
Company Description
Vir Biotechnology
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
VIR Company Deck
VIR Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed predominantly positive momentum: a strategically valuable collaboration with Astellas that provides significant upfront capital, shared development burden, and global commercialization reach, together with compelling Phase I clinical data for VIR-5500 showing dose-dependent deep PSA declines, radiographic responses (45% ORR in RECIST-evaluable at high doses), limited high-grade CRS, and encouraging durability signals. Financial discipline improved in 2025 (R&D down 10%, SG&A down 23%, net loss reduced ~16%), and the company reports a strengthened cash position and runway into Q2 2028 when incorporating recent agreements. Key risks remain: the dataset is still early and relatively small, there are isolated higher-grade safety events (including two blurred-vision treatment-related discontinuations and one early Grade 3 CRS), certain payments are subject to third-party obligations and regulatory waiting periods, and continued dose optimization and longer follow-up are needed to confirm durability and broader applicability. Overall, the positives (deal, clinical signal, safety profile, financial improvements) substantially outweigh the current lowlights, though execution and maturation of data remain critical.View all VIR earnings summariesVIR Stock 12 Month Forecast
Average Price Target
$20.86
▲(129.23% Upside)
Technical Analysis
Ownership Overview
10.72% Insiders
12.16% Mutual Funds
29.24% Other Institutional Investors
29.26% Public Companies and Individual Investors